Mark Ginski Ph.D has been appointed vice president of Corticotropin product development at ANI Pharmaceuticals, Inc., effective May 23, 2016. 
 
Mark J. Ginski is an accomplished scientist with more than 20 years of experience in API and drug product development, formulation, analytical development and API and drug product manufacturing. Dr. Ginski has held various positions in specialty drug development with Shire Pharmaceuticals, Alba Therapeutics, Cerecor Inc, Questcor Pharmaceuticals and most recently, Mallinckrodt Pharmaceuticals, where he was the senior director, CMC and Operations for Autoimmune and Rare Diseases. 
 
Arthur S. Przybyl, ANI’s president and chief executive officer said, “I am pleased that Mark has joined ANI to help lead the advancement of our most exciting pipeline opportunity, the re-commercialization of our corticotrophin NDAs. I am confident that Mark’s diverse and highly relevant experience will bring valuable insights to this project. We intend to further expand ANI’s bench strength on this critical project and add additional subject matter experts in the near future.”